U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H14NO.Cl
Molecular Weight 138.624
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHOLINE CHLORIDE C-11

SMILES

[Cl-].C[N+](C)([11CH3])CCO

InChI

InChIKey=SGMZJAMFUVOLNK-ULWFUOSBSA-M
InChI=1S/C5H14NO.ClH/c1-6(2,3)4-5-7;/h7H,4-5H2,1-3H3;1H/q+1;/p-1/i1-1;

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H13NO
Molecular Weight 102.1636
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Choline C 11 injection was approved to help diagnose recurrent prostate cancer. It is used for a procedure called positron emission tomography (PET) scan to detect tumors that are not detectable by other scanning procedures, such as bone scan, computed tomography (CT), or magnetic resonance imaging (MRI). Choline C 11 is a radioactive diagnostic agent, the analog of choline. Choline is involved in the synthesis of the structural components of cell membranes, as well as modulation of transmembrane signaling. Increased phospholipid synthesis (i.e., increased uptake of choline) has been associated with cell proliferation and the transformation process that occurs in tumor cells. Recently, Choline C 11 PET was studied for diagnosis the patients with hepatocellular carcinoma; although the phase II of clinical trials was not begun.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
CHOLINE C-11

Approved Use

Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration.

Launch Date

2012
Diagnostic
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion.
2017 Oct
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer.
2017 Oct 21
11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer.
2017 Sep 12
Contribution of (11)C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml.
2018 May-Jun

Sample Use Guides

The recommended dose is 370 to 740 MBq (10 to 20 mCi) administered as a bolus intravenous injection. The radioactivity dose (370 to 740 MBq, 10 to 20 mCi) is chosen based on patient body dimensions and the characteristics of the image acquisition system.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:54:16 GMT 2023
Edited
by admin
on Sat Dec 16 01:54:16 GMT 2023
Record UNII
381E0BTR5Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHOLINE CHLORIDE C-11
Common Name English
ETHANAMINIUM, 2-HYDROXY-N,N-DIMETHYL-N-(METHYL-11C)-, CHLORIDE (1:1)
Common Name English
Code System Code Type Description
PUBCHEM
14989482
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
DRUG BANK
DB09277
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
SMS_ID
300000013060
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID50236498
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
CHEBI
72321
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
FDA UNII
381E0BTR5Q
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
CAS
87591-54-6
Created by admin on Sat Dec 16 01:54:16 GMT 2023 , Edited by admin on Sat Dec 16 01:54:16 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY